Skip to main content

Spaventa Andrew's Form 4 filing

Singular Genomics Systems, Inc.OMIC · filed Nov 20, 2023

Accession no.
0001209191-23-056071
Filed
Nov 20, 2023, 4:31 PM ET
Trade date
Nov 16-17, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $49.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Spaventa AndrewCIK 0001859701Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2023Common StockPPurchaseAcquired+43,468$0.4108F1+$17,856.653,986,206Indirect
Nov 17, 2023Common StockPPurchaseAcquired+75,000$0.4234F2+$31,7554,061,206Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.3770 to $0.4200, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.4200 to $0.4456, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)